Boehringer Ingelheim to distribute Synvisc in France:
This article was originally published in Clinica
Executive Summary
Boehringer Ingelheim has won exclusive distribution rights to Synvisc in France, Algeria, Morocco and Tunisia. The viscosupplementation treatment for osteoarthritis of the knee was developed by US company Biomatrix and is based on its hylan technology. Under the terms of the agreement, which is valid for up to 15 years, Biomatrix, which is based in Ridgefield, New Jersey, will receive a licensing fee of up to $8 million, including up-front fees and milestone payments. German pharmaceutical company Boehringer Ingelheim intends to launch the product in France in early 1997.